[ 會員# ] shenshifu
孕前基因檢查
請問現在有一種做産前基因檢測的技術來診斷未來嬰兒(BB)是否健康?想問題: 請問一下這種檢查有沒有作用?是怎樣的?謝謝。
王予婷醫生回覆:
7/31/2014
7/31/2014
Hello
Are you referring to non-invasive prenatal testing for the fetus?
I have taken for your reference an abstract from the RCOG Scientific Impact Paper No. 15
March 2014
‘Fetal genetic testing and aneuploidy diagnosis have until recently both needed invasive diagnostic
sampling procedures carrying a small but significant risk of miscarriage. In 1997 the presence of cell-free
fetal DNA (cffDNA) in the maternal circulation was reported.1 Fetal DNA comes from the placenta,2 can
be detected from the first trimester of pregnancy onwards3 and is rapidly cleared from the maternal
circulation after delivery.4 Maternal blood is therefore a reliable source of material for prenatal diagnosis.
However, the cffDNA is mixed with a larger proportion of maternal cell-free DNA and current
methodologies do not allow complete separation of fetal from maternal DNA in vitro. Therefore, the
first applications of this phenomenon focused on the detection, or exclusion of, paternally-inherited fetal
DNA sequences that are not present in the mother, such as Y chromosome sequences in pregnancies with
a male fetus or rhesus D (RhD) sequences in women who are RhD-negative. Recently, DNA sequencing
technologies have allowed very precise relative quantification of DNA fragments and so the detection of
the extra material resulting from fetal chromosome trisomy within the maternal plasma DNA can now
be performed in a robust manner.’
‘Non-invasive prenatal testing NIPT using maternal plasma DNA is available for several conditions. Obstetricians have used NIPT to guide management of women who are RhD-negative and whose fetuses are at risk of HDFN for many
years and guidelines should already reflect this change in practice. Fetal sex determination for clinical
indications in pregnancies at high sex-linked genetic risk is also established practice. Testing for
aneuploidy and especially Down syndrome by maternal plasma MPS is now available commercially but
while the test result is much more accurate than existing screening strategies, it is still not a diagnostic
assay. Hence, the term ‘non-invasive testing’ is currently used.’
These NIPT tests are available in the private clinics in Hong Kong.
Cheers,
Are you referring to non-invasive prenatal testing for the fetus?
I have taken for your reference an abstract from the RCOG Scientific Impact Paper No. 15
March 2014
‘Fetal genetic testing and aneuploidy diagnosis have until recently both needed invasive diagnostic
sampling procedures carrying a small but significant risk of miscarriage. In 1997 the presence of cell-free
fetal DNA (cffDNA) in the maternal circulation was reported.1 Fetal DNA comes from the placenta,2 can
be detected from the first trimester of pregnancy onwards3 and is rapidly cleared from the maternal
circulation after delivery.4 Maternal blood is therefore a reliable source of material for prenatal diagnosis.
However, the cffDNA is mixed with a larger proportion of maternal cell-free DNA and current
methodologies do not allow complete separation of fetal from maternal DNA in vitro. Therefore, the
first applications of this phenomenon focused on the detection, or exclusion of, paternally-inherited fetal
DNA sequences that are not present in the mother, such as Y chromosome sequences in pregnancies with
a male fetus or rhesus D (RhD) sequences in women who are RhD-negative. Recently, DNA sequencing
technologies have allowed very precise relative quantification of DNA fragments and so the detection of
the extra material resulting from fetal chromosome trisomy within the maternal plasma DNA can now
be performed in a robust manner.’
‘Non-invasive prenatal testing NIPT using maternal plasma DNA is available for several conditions. Obstetricians have used NIPT to guide management of women who are RhD-negative and whose fetuses are at risk of HDFN for many
years and guidelines should already reflect this change in practice. Fetal sex determination for clinical
indications in pregnancies at high sex-linked genetic risk is also established practice. Testing for
aneuploidy and especially Down syndrome by maternal plasma MPS is now available commercially but
while the test result is much more accurate than existing screening strategies, it is still not a diagnostic
assay. Hence, the term ‘non-invasive testing’ is currently used.’
These NIPT tests are available in the private clinics in Hong Kong.
Cheers,
以上資料只供參考,不能作診症用途,
請與家庭醫生查詢並作出適合治療。
如有身體不適請即求診,切勿延誤治療。
若資料有所漏誤,本網及相關資料提供者恕不負責。
請與家庭醫生查詢並作出適合治療。
如有身體不適請即求診,切勿延誤治療。
若資料有所漏誤,本網及相關資料提供者恕不負責。

Angel Tong : 2016年能接生(開刀)的醫生
有了14週,前天去找屯門的醫生檢查才知道因為保險新例令很多婦產科醫生不接生⋯接著打電話問了一些醫務所又剛好7月.......Macy Ng : 驗血check bb性別
驗血check bb性別及健康情況,想問係咪每間都有得做? 大概幾錢?.......Rb chann : 陰道發炎?
如下體有異味應怎樣處理 是否代表陰道發炎?.......cobe1010 : 脫髮 月經紊亂
近兩個月經常脫髮,頭髮比以前油,會痕有時會有頭瘡。另外黎m 黎得好亂,月頭黎一次,之後月尾又會黎,請問醫生兩.......yiplukyan : 持續幾日流黃色分泌物
這個月15號來完m後就持續幾日流黃色分泌物之後又間中流咖啡色分泌物,接住又流左一d深紅分泌物,持續十日 ,d分.......LK Chan : 非典型腺細胞(續問)
Dear Dr Ong, Thank you very much for your reply. Do y....... 發出提問使用細則
致王予婷醫生 提問